Latest News for: Wamd

Edit

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL FOR RECOMBINANT ANTI-VEGF HUMANISED MONOCLONAL ANTIBODY OPHTHALMIC INJECTION HLX04-O FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (wAMD) APPROVED IN AN EU COUNTRY (LATVIA) (Shanghai Henlius Biotech Inc)

Public Technologies 20 Apr 2021
APPLICATION FOR CLINICAL TRIAL FOR RECOMBINANT ANTI-VEGF HUMANISED MONOCLONAL ANTIBODY OPHTHALMIC INJECTION HLX04-O FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (wAMD) APPROVED IN AN EU COUNTRY (LATVIA) INTRODUCTION ... macular degeneration (wAMD) indications.
Edit

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL FOR RECOMBINANT ANTI-VEGF HUMANIZED MONOCLONAL ANTIBODY OPHTHALMIC INJECTION HLX04-O FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (wAMD) APPROVED BY THERAPEUTIC GOODS ADMINISTRATION, AUSTRALIA (Shanghai Henlius Biotech Inc)

Public Technologies 29 Jan 2021
APPLICATION FOR CLINICAL TRIAL FOR RECOMBINANT ANTI-VEGF HUMANIZED MONOCLONAL ANTIBODY OPHTHALMIC INJECTION HLX04-O FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (wAMD) APPROVED BY THERAPEUTIC GOODS ADMINISTRATION, AUSTRALIA INTRODUCTION.
Edit

Opthea to Host Key Opinion Leader Symposium on wAMD and DME 2 pages ?Kb

Public Technologies 28 Jul 2020
The text version of this document in not available ... Disclaimer ... (noodl. 54775274) .
  • 1

Most Viewed

×